For the second consecutive year, the pharmaceutical industry saw its reputation slip among patient advocacy groups, largely due to ongoing concerns over pricing issues, according to a new survey.
Of more than 2,500 groups queried, 56% reported the industry had an “excellent” or “good” reputation as it goes about the business of developing and providing medicines. Although the findings suggest a clear majority were mostly satisfied with drug companies, this marked a second consecutive annual decline — albeit, a slight one — after several years in which the industry was seen more positively.
The previous survey found that 57% of the groups indicated the industry had an “excellent” or “good” reputation. The back-to-back declines come after 60% of patient groups believed the industry fared well thanks to the initial response of many companies to quickly develop salves for the Covid-19 pandemic. In 2021, for instance, 59% of companies scored highly, compared with 41% in 2018.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
